Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

✓ Peer-reviewed alzhub usefulness score 52 out of 100. Brain scans and imaging

Topic: Amyloid, tau and blood-test diagnosis

Objective Alzheimer disease (AD) and frontotemporal lobar degeneration (FTLD) are hypothesized to cause clinically distinct forms of primary progressive aphasia (PPA) that predominantly affect expressive speech. AD is thought to cause logopenic progressive aphasia (LPA), and FTLD may cause progressive nonfluent aphasia (PNFA). We sought to determine the value of clinical characterization, neuropsychological analysis, and MRI atrophy in predicting pathology of LPA and PNFA. Methods Patients with LPA (n = 19) and patients with PNFA (n = 19) were evaluated with neuropsychological assessments, structural MRI, CSF analysis, and neuropathologic examination. Results Twelve of 19 patients with LPA (63%) and 6 of 19 patients with PNFA (32%) had neuropathologic findings or CSF biomarkers consistent with AD. Neuropsychological testing showed that naming was more impaired in patients with AD, and letter-guided fluency was more affected in patients with a non-AD disorder. Voxel-based morphometry analysis revealed that in patients with AD, patients with LPA and PNFA had significant posterior-superior temporal atrophy; in patients with non-AD, patients with LPA had peri-Sylvian atrophy and patients with PNFA had dorsolateral prefrontal and insular atrophy. Receiver operator characteristic curve analysis showed that combining neuropsychological testing with MRI atrophy pattern had 90% specificity for pathology or CSF biomarkers consistent with AD, and combining clinical features with neuropsychological analysis had 100% sensitivity for pathology or CSF biomarkers consistent with AD. Conclusions Neither PPA phenotyping nor imaging alone is a reliable predictor of pathology. Multimodal predictors, such as combining neuropsychological testing with MRI analysis, can improve noninvasive prediction of underlying pathology in nonfluent forms of PPA.

Key findings

Why it matters

Among patients with two forms of primary progressive aphasia, many had pathology or biomarkers consistent with Alzheimer's disease, and combining neuropsychological testing with MRI atrophy patterns improved identification. This is about predicting underlying pathology, not about treating or preventing Alzheimer's disease.

Study details

How this study scored 52/100
How this study's score is builtJournal tier 9 of 10; Journal's citation record 4 of 4; Study design 0 of 12; Strength of evidence 1 of 5; Peer-review validation 10 of 10; How recent 1 of 5; Sample size 1 of 4; Effect reported 0 of 3; Studied in people 3 of 3; Randomised / blinded 0 of 2; Times cited 5 of 7; Citations per year 2 of 5; Impact for its field and year 4 of 6; Cited by studies here 2 of 6; Still being cited 1 of 4; Senior author's track record 3 of 4; Institution's track record 2 of 3; Multi-centre collaboration 2 of 3; Indexed in PubMed 2 of 2; Free to read 0 of 2. Total 52 of 100.52 of 100 points earned48 not earned

Published in a leading specialty journal. Scored zero for study design, effect reported and randomised / blinded because the record does not state it.

ComponentPointsWhy
Journal tier 9 / 10 Tier 2 — leading specialty journal (Neurology)
Journal's citation record 4 / 4 Neurology: journal h-index 525 (OpenAlex, 2026-10-29)
Study design 0 / 12 No study design recorded — scores zero, not guessed (not stated in the record — scored 0)
Strength of evidence 1 / 5 Rated “low” in our summary
Peer-review validation 10 / 10 Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent 1 / 5 2010 — within 20 year(s) of the newest study here
Sample size 1 / 4 19 participants
Effect reported 0 / 3 No effect size reported — scores zero (not stated in the record — scored 0)
Studied in people 3 / 3 Studied in people (participant count stated)
Randomised / blinded 0 / 2 No randomisation or blinding stated — scores zero (not stated in the record — scored 0)
Times cited 5 / 7 Cited 102 times (OpenAlex, 2026-10-10)
Citations per year 2 / 5 5.7 citations a year over 18 year(s) since 2010
Impact for its field and year 4 / 6 Cited 9.6× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here 2 / 6 Cited by 6 other studies in this library
Still being cited 1 / 4 Cited 3 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record 3 / 4 Last-listed author Owen A. Ross: h-index 95 (OpenAlex, whole career)
Institution's track record 2 / 3 University of Pennsylvania: institution h-index 1,859 (OpenAlex)
Multi-centre collaboration 2 / 3 OpenAlex lists 4 institution(s) in 1 country
Indexed in PubMed 2 / 2 Indexed in PubMed (PMID 20713948)
Free to read 0 / 2 Behind a paywall — scores zero
Total 52 / 100 —

What each of these 20 components measures, and what this score is not →

Read the original

Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record names 8 authors; APA and Vancouver show the first six, BibTeX and the downloads carry all of them. Check the citation against the original before you use it.

APA 7th

Hu, W. T., McMillan, C., Libon, D., Leight, S., Forman, M., Lee, V. M., et al. (2010). Multimodal predictors for Alzheimer disease in nonfluent primary progressive aphasia. Neurology. https://doi.org/10.1212/wnl.0b013e3181ed9c52

Vancouver

Hu WT, McMillan C, Libon D, Leight S, Forman M, Lee VM, et al. Multimodal predictors for Alzheimer disease in nonfluent primary progressive aphasia. Neurology. 2010. doi:10.1212/wnl.0b013e3181ed9c52. PMID: 20713948.

BibTeX

@article{hu2010-20713948,
  author  = {Hu, W. T. and McMillan, C. and Libon, D. and Leight, S. and Forman, M. and Lee, V. M. and Trojanowski, J. Q. and Grossman, M.},
  title   = {{Multimodal predictors for Alzheimer disease in nonfluent primary progressive aphasia}},
  journal = {Neurology},
  year    = {2010},
  doi     = {10.1212/wnl.0b013e3181ed9c52},
  pmid    = {20713948},
  url     = {https://doi.org/10.1212/wnl.0b013e3181ed9c52}
}

Studies this one cites

Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 15.

Later studies that cite this one

6 studies in the alzhub library list this one in their references.

Related studies in Brain scans and imaging

Similar studies

More on Brain scans and imaging

See all studies in Brain scans and imaging →